BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33806229)

  • 21. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.
    Zamarin D; Palese P
    Future Microbiol; 2012 Mar; 7(3):347-67. PubMed ID: 22393889
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer.
    Chai Z; Zhang P; Fu F; Zhang X; Liu Y; Hu L; Li X
    Virol J; 2014 May; 11():84. PubMed ID: 24885546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
    Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
    Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regression of solid breast tumours in mice by Newcastle disease virus is associated with production of apoptosis related-cytokines.
    Raihan J; Ahmad U; Yong YK; Eshak Z; Othman F; Ideris A
    BMC Cancer; 2019 Apr; 19(1):315. PubMed ID: 30947706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
    Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
    J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
    Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
    Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
    Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
    Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.
    García-Romero N; Palacín-Aliana I; Esteban-Rubio S; Madurga R; Rius-Rocabert S; Carrión-Navarro J; Presa J; Cuadrado-Castano S; Sánchez-Gómez P; García-Sastre A; Nistal-Villan E; Ayuso-Sacido A
    Cells; 2020 Jun; 9(6):. PubMed ID: 32516884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
    Vijayakumar G; Zamarin D
    Methods Mol Biol; 2020; 2058():133-154. PubMed ID: 31486036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Newcastle disease virus strain AF2240 as an oncolytic virus: A review.
    Kalyanasundram J; Hamid A; Yusoff K; Chia SL
    Acta Trop; 2018 Jul; 183():126-133. PubMed ID: 29626432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma.
    Zulkifli MM; Ibrahim R; Ali AM; Aini I; Jaafar H; Hilda SS; Alitheen NB; Abdullah JM
    Neurol Res; 2009 Feb; 31(1):3-10. PubMed ID: 18937888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain.
    Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J
    Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
    Schirrmacher V
    Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of Apoptosis Induction by Newcastle Disease Virus LaSota Strain in Human Breast Carcinoma Cells.
    Kalantari A; Farashi Bonab S; Keyvanfar H; Mortazavi P
    Arch Razi Inst; 2020 Oct; 75(3):367-376. PubMed ID: 33025777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
    Vijayakumar G; Palese P; Goff PH
    EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells.
    Wang J; Li M; Li M
    Vet Comp Oncol; 2023 Sep; 21(3):520-532. PubMed ID: 37282822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.
    Zamarin D; Martínez-Sobrido L; Kelly K; Mansour M; Sheng G; Vigil A; García-Sastre A; Palese P; Fong Y
    Mol Ther; 2009 Apr; 17(4):697-706. PubMed ID: 19209145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apoptin enhances the oncolytic properties of Newcastle disease virus.
    Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S
    Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models.
    Cuadrado-Castano S; Ayllon J; Mansour M; de la Iglesia-Vicente J; Jordan S; Tripathi S; García-Sastre A; Villar E
    Mol Cancer Ther; 2015 May; 14(5):1247-58. PubMed ID: 25761895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus.
    Pfirschke C; Schirrmacher V
    Int J Oncol; 2009 Apr; 34(4):951-62. PubMed ID: 19287952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.